FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896914935> ?p ?o ?g. }

• W2896914935 abstract "Background Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors. An association between certolizumab pegol (CP) serum levels and response has previously been found in patients (pts) with rheumatoid arthritis.1 Data for pts with axial spondyloarthritis (axSpA) are lacking. Objectives To examine the association between serum CP levels and treatment response in pts with axSpA and to identify a therapeutic target level. Methods Patients with a clinical diagnosis of axSpA starting standard treatment with CP included in the NOR-DMARD study with biobank sample at 3 months follow-up, were included in the present analyses. Serum drug levels (non-trough) were analysed with an in-house immunofluorometric assay automated on the AutoDELFIA immunoassay platform. Associations between CP level and improvement in ASDAS-CRP and response (defined as ASDAS clinically important improvement (CII)) were assessed by multivariable linear and logistic regression (adjusting for age, sex and prior bDMARD (Y/N)), respectively. Results Median serum drug level at 3 month follow up was 35.0 mg/L (IQR 21.3–45.3) in 116 pts. Response data were available in 110/116 patients. Serum CP level ≥20 mg/L was associated with improvement in ASDAS at 3 months (β=0.55, (95% CI 0.12–1.98), p=0.01). Serum CP level ≥20 mg/L was associated with ASDAS CII at 3 months (OR 3.4 (95% CI 1.0–11.1, p=0.045)). Only 18.2% of pts with CP level Conclusions Serum CP level was associated with clinical response after 3 months of treatment in pts with axSpA. We suggest 20 mg/L as a lower target level for non-trough samples. No additional benefit of having a certolizumab level over 40 mg/L was observed. These results suggest that a therapeutic level of 20–40 mg/L can be implemented in clinical practice for non-trough serum samples in pts with axSpA. Reference [1] Jani M, et al. Ann Rheum Dis2017;76(1):208–13. Disclosure of Interest J. E. Gehin Consultant for: Roche, S. Syversen Consultant for: Roche, D. Warren: None declared, G. Goll Consultant for: Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Eli Lilly, Novartis, Pfizer, MSD, Roche, UCB, J. Sexton: None declared, E. Strand Consultant for: Pfizer, T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, UCB, N. Bolstad Consultant for: Pfizer, Orion Pharma, Napp pharmaceuticals, Takeda, Roche, E. Lie: None declared" @default.
• W2896914935 created "2018-10-26" @default.
• W2896914935 creator A5014171233 @default.
• W2896914935 creator A5024541408 @default.
• W2896914935 creator A5033041859 @default.
• W2896914935 creator A5039628338 @default.
• W2896914935 creator A5045918609 @default.
• W2896914935 creator A5052056865 @default.
• W2896914935 creator A5058070491 @default.
• W2896914935 creator A5071139097 @default.
• W2896914935 creator A5077936932 @default.
• W2896914935 date "2018-06-01" @default.
• W2896914935 modified "2023-09-27" @default.
• W2896914935 title "SAT0261 Certolizumab pegol serum levels ≥20 mg/l are associated with treatment response in patients with axial spondyloarthritis. data from the nor-dmard study" @default.
• W2896914935 doi "https://doi.org/10.1136/annrheumdis-2018-eular.5252" @default.
• W2896914935 hasPublicationYear "2018" @default.
• W2896914935 type Work @default.
• W2896914935 sameAs 2896914935 @default.
• W2896914935 citedByCount "0" @default.
• W2896914935 crossrefType "proceedings-article" @default.
• W2896914935 hasAuthorship W2896914935A5014171233 @default.
• W2896914935 hasAuthorship W2896914935A5024541408 @default.
• W2896914935 hasAuthorship W2896914935A5033041859 @default.
• W2896914935 hasAuthorship W2896914935A5039628338 @default.
• W2896914935 hasAuthorship W2896914935A5045918609 @default.
• W2896914935 hasAuthorship W2896914935A5052056865 @default.
• W2896914935 hasAuthorship W2896914935A5058070491 @default.
• W2896914935 hasAuthorship W2896914935A5071139097 @default.
• W2896914935 hasAuthorship W2896914935A5077936932 @default.
• W2896914935 hasBestOaLocation W28969149351 @default.
• W2896914935 hasConcept C126322002 @default.
• W2896914935 hasConcept C151956035 @default.
• W2896914935 hasConcept C2776213234 @default.
• W2896914935 hasConcept C2776215756 @default.
• W2896914935 hasConcept C2776260265 @default.
• W2896914935 hasConcept C2777077863 @default.
• W2896914935 hasConcept C2777226972 @default.
• W2896914935 hasConcept C2777453003 @default.
• W2896914935 hasConcept C2777575956 @default.
• W2896914935 hasConcept C2778579456 @default.
• W2896914935 hasConcept C2780132546 @default.
• W2896914935 hasConcept C2781290027 @default.
• W2896914935 hasConcept C71924100 @default.
• W2896914935 hasConcept C90924648 @default.
• W2896914935 hasConceptScore W2896914935C126322002 @default.
• W2896914935 hasConceptScore W2896914935C151956035 @default.
• W2896914935 hasConceptScore W2896914935C2776213234 @default.
• W2896914935 hasConceptScore W2896914935C2776215756 @default.
• W2896914935 hasConceptScore W2896914935C2776260265 @default.
• W2896914935 hasConceptScore W2896914935C2777077863 @default.
• W2896914935 hasConceptScore W2896914935C2777226972 @default.
• W2896914935 hasConceptScore W2896914935C2777453003 @default.
• W2896914935 hasConceptScore W2896914935C2777575956 @default.
• W2896914935 hasConceptScore W2896914935C2778579456 @default.
• W2896914935 hasConceptScore W2896914935C2780132546 @default.
• W2896914935 hasConceptScore W2896914935C2781290027 @default.
• W2896914935 hasConceptScore W2896914935C71924100 @default.
• W2896914935 hasConceptScore W2896914935C90924648 @default.
• W2896914935 hasLocation W28969149351 @default.
• W2896914935 hasOpenAccess W2896914935 @default.
• W2896914935 hasPrimaryLocation W28969149351 @default.
• W2896914935 isParatext "false" @default.
• W2896914935 isRetracted "false" @default.
• W2896914935 magId "2896914935" @default.
• W2896914935 workType "article" @default.